60
Participants
Start Date
June 1, 2022
Primary Completion Date
August 31, 2024
Study Completion Date
August 31, 2024
Topical anti-Staphylococcus bacteriophage therapy
Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
CHRU de Nîmes - Hôpital Universitaire de Réadaptation du Grau du Roi, Le Grau-du-Roi
CHRU de Toulouse - Hôpital de Rangueil, Toulouse
CHU de Bordeaux - Hôpital Pellegrin, Bordeaux
CHU de Nantes - Hôtel Dieu, Nantes
CH de Tourcoing, Tourcoing
APHP - Hôpital Lariboisière, Paris
APHP - Groupe Hospitalier Pitié-Salpetrière, Paris
CH Intercommunal de Villeneuve-Saint-Georges, Villeneuve-Saint-Georges
Institut Robert Merle d'Aubigné, Valenton
Collaborators (1)
Phaxiam Therapeutics
INDUSTRY
Centre Hospitalier Universitaire de Nīmes
OTHER